Skip Navigation

European Heart Journal 1995 16(Supplement K):13-22; doi:10.1093/eurheartj/16.suppl_K.13
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cambien, F.
Right arrow Articles by Evans, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cambien, F.
Right arrow Articles by Evans, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Angiotensin I converting enzyme gene polymorphism and coronary heart disease

F. Cambien*, and A. Evans{dagger}

* INSERM, Paris, France
{dagger} Department of Epidemiology and Public Health, The Queens' University Belfast, Northern Ireland

Correspondence: François Cambien, INSERM S.C.7, 17, rue du Fer à Moulin, 75005 Paris, France

Genetic variations in the renin-angiotensin and kallikrein-kinin systems could prove to be significant pathophysiological mechanisms affecting coronary heart disease (CHD), particularly given the powerful vasoactivity of products such as angiotensin II and bradykinin. Indeed, studies show that angiotensin converting enzyme (ACE) gene polymorphism is associated with an increased risk of myocardial infarction and death, even in otherwise low-risk subjects. Genetic differences do not appear to be a risk factor for atherosclerosis or hypertension, however. Because ACE polymorphism modulates local production of angiotensin II, a powerful coronary vasoconstrictor, it may influence left ventricular mass in general as well as in coexisting disease states such as hypertension and cardiomyopathy. However, further study is needed to clarify the implications of ACE polymorphism in patients with left ventricular hypertrophy. Interactions between ACE and angiotensin II type-1 receptors may have clinical implications for preventing and managing CHD. Screening for genetic risk, as evidenced by certain variants in receptor coding sequence; may prove worthwhile if detrimental effects can be countered by drugs such as ACE inhibitors and angiotensin II receptor blockers. Given the important roles of angiotensin II and bradykinin as modulators of cellular growth and of vasoactivity, deleterious and beneficial effect at different stages of the atherosclerotic process and during acute events leading to myocardial infarction or sudden death can be suspected.

Key Words: Angiotensin converting enzyme gene polymorphism • coronary atherosclerosis • coronary heart disease • myocardial infarction • ventricular hypertrophy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
W. Huang, C. Xie, H. Zhou, T. Yang, and M. Sun
Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients
Eur J Heart Fail, January 1, 2004; 6(1): 23 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
F. Mehraban and J. E. Tomlinson
Application of industrial scale genomics to discovery of therapeutic targets in heart failure
Eur J Heart Fail, December 1, 2001; 3(6): 641 - 650.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.